Rifes, Pedro
Isaksson, Marc
Rusimbi, Charlotte
Ramón Santonja, Adrián
Nelander, Jenny
Laurell, Thomas
Kirkeby, Agnete http://orcid.org/0000-0001-8203-6901
Funding for this research was provided by:
Novo Nordisk Fonden (NNF18OC0030286, NNF21CC0073729)
Innovationsfonden (4108-00008A)
Knut och Alice Wallenbergs Stiftelse
Vetenskapsrådet (70862601)
Crafoordska Stiftelsen
Thorsten och Elsa Segerfalks Stiftelse
Tore Nilsons Stiftelse för Medicinsk Forskning
Stiftelsen Forska Utan Djurförsök
Lund University
Article History
Received: 13 March 2023
Accepted: 20 November 2023
First Online: 10 December 2023
Declarations
:
: Not applicable.
: Not applicable.
: The authors declare that they have no competing interests in relation to the current study. A.K. is the owner of Kirkeby Cell Therapy APS, performs paid consultancy to Novo Nordisk A/S and is a co-inventor on patents WO2016162747A2/A3 and WO2019016113A1 on the generation of DA cells for treatment of PD. P.R. is now an employee of the company Bioneer, developing in vitro disease models from stem cells.